PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsGene therapy given green light in Europe

BioNews

Gene therapy given green light in Europe

Published 12 April 2016 posted in News and appears in BioNews 846

Author

Rebecca Carr

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A gene therapy for children with a rare but life-threatening genetic disorder that severely weakens the immune system has been recommended for approval by the European Medicines Agency...

A gene therapy for children with a rare but life-threatening genetic disorder that severely weakens the immune system has been recommended for approval by the European Medicines Agency.

Strimvelis has been developed by Italian scientists in conjunction with GlaxoSmithKline and is aimed at children with ADA-SCID (adenosine deaminase deficiency, severe combined immunodeficiency), where a single genetic defect prevents the development of a robust immune system. Children with ADA-SCID are susceptible to multiple infections and without treatment they rarely live beyond two years of age. The condition is sometimes known as 'bubble boy disease' due to children with the condition sometimes having to live in plastic, germ-free chambers. 

Patients with ADA-SCID can also suffer serious liver and kidney problems, growth problems and hearing loss. There are believed to be around 350 children worldwide who have been born with the condition.

At present, ADA-SCID sufferers often undergo bone-marrow transplants, which may offer them a good chance at survival. The success of such transplants depends on how good the donor match is, and around one in four babies with a well-matched family member will be effectively cured. This option is not possible for all candidates, however, and so Strimvelis is primarily intended for those who lack a suitable transplant donor.

The treatment involves taking the patients own stem cells and inserting a working copy of the gene that produces adenosine deaminase, needed for the production of white blood cells. The cells are then injected back into the patient in order to correct the root cause of ADA-SCID. Since the manipulated cells are the patient's own, problems traditionally associated with transplant procedures such as host rejection and increased infection due to immunosuppressive therapy are avoided.

However, due to the very short shelf life of stem cells, the procedure must take place within a short time frame, meaning that the procedure is only currently available in the Milan hospital where it was first developed.

Other barriers to currently accessing the drug are likely to include cost. The first gene therapy, Glybera, intended to treat rare genetic blood disorders, was notorious for its high price tag set at $1 million per patient to administer (reported in BioNews 782). While GlaxoSmithKline has not indicated a price for Strimvelis just yet, Reuters reports that a source close to the company has said that it would cost 'very significantly less than $1million'.

Success rates for the treatment have been promising. Of the 22 children treated with the therapy in the past 14 years, doctors report that all are still alive, with most not needing any further treatment.

Strimvelis was designated as an orphan medicinal product in 2005, providing medicine developers with additional incentives such as fee reductions for scientific advice and the possibility of gaining extended market exclusivity.

GlaxoSmithKline has other gene therapies under development with Italian researchers, including a treatment for metachromatic leukodystrophy and Wiskott-Aldrich syndrome.

Now that the European Medicines Agency has recommended approval of the drug, the European Commission will to take the final decision on whether it should be marketed for clinical use across the European Union.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 November 2017 • 2 minutes read

NHS will fund gene therapy for bubble boy syndrome

by Jen Willows

NICE has approved a gene therapy for children with a rare disorder that leaves them with no functioning immune system...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
14 September 2016 • 3 minutes read

Second gene therapy wins approval in Europe

by Rachel Reeves

The European Commission has granted marketing authorisation for a gene therapy to treat children with an extremely rare, life-threatening genetic disorder...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 September 2016 • 2 minutes read

Study brings sickle-cell gene therapy one step closer

by Dr Nicoletta Charolidi

A genetically engineered virus that triggers the production of an alternative form of haemoglobin has reversed the symptoms of sickle cell disease in mice...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
18 December 2015 • 3 minutes read

'Suicide gene therapy' for prostate cancer shows promise

by Dr Lone Hørlyck

A treatment for prostate cancer, combining radiotherapy and a new type of gene therapy, is both safe and effective, a study has found...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
14 December 2015 • 2 minutes read

Gene therapy shows promise at treating immunodeficiency

by Dr Jamie Heather

Two patients enrolled in a clinical trial of a gene therapy to treat severe congenital immunodeficiency have shown signs of substantial improvement in their condition...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
4 September 2015 • 2 minutes read

Postmortem findings hint at Alzheimer's gene therapy effect

by Chris Hardy

An experimental gene therapy used in patients with Alzheimer's disease appears to slow down neural degeneration....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 October 2014 • 2 minutes read

Revamped gene therapy for 'bubble boy' immune condition does well in trial

by Dr Jamie Heather

Gene therapy to treat children with 'bubble boy syndrome' seems to be both safe and effective, a study published in the New England Journal of Medicine has found...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
2 November 2012 • 2 minutes read

Gene therapy approved in Europe for first time

by Dr Lucy Spain

The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat a rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved for the Western market and offers the first therapeutic treatment for people with LPLD....

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Second Chinese team create genetically modified human embryos

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856